apixaban

FDA Drug Profile — ELIQUIS, ELIQUIS 30-Day Starter Pack, ELIQUIS SPRINKLE, apixaban

apixaban is listed in the FDA National Drug Code directory with 45 NDC codes, marketed under brand names including ELIQUIS, ELIQUIS 30-Day Starter Pack, ELIQUIS SPRINKLE. Available dosage forms: tablet, film coated, tablet, for suspension, kit, capsule, powder.

Drug details

Generic Name
apixaban
Brand Names
ELIQUIS, ELIQUIS 30-Day Starter Pack, ELIQUIS SPRINKLE, apixaban
Application Number
NDA202155
Sponsor
Aphena Pharma Solutions - Tennessee, LLC
NDC Codes
45
Dosage Forms
TABLET, FILM COATED, TABLET, FOR SUSPENSION, KIT, CAPSULE, POWDER
Routes
ORAL
Active Ingredients
APIXABAN

Indications and Usage

1 INDICATIONS AND USAGE ELIQUIS is a factor Xa inhibitor indicated: • to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. (1.1) • for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery. (1.2) • for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE in adult patients following initial therapy. (1.3 , 1.4 , 1.5) • Treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth and older after at least 5 days of initial anticoagulant treatment. (1.6) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis ELIQUIS is indicated for the treatment of adults with deep vein thrombosis (DVT). 1.4 Treatment of Pulmonary Embolism ELIQUIS is indicated for the treatment of adults with pulmonary embolism (PE). 1.5 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and Pulmonary Embolism ELIQUIS is indicated to reduce the risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) in adult patients following initial therapy. 1.6 Treatment of Venous Thromboembolism and Reduction in the Risk of Recurrent Venous Thromboembolism in Pediatric Patients ELIQUIS is indicated for the treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth and older after at least 5 days of initial anticoagulant treatment.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.